| INTRODUCTION
In recent years, advances in the field of genetics have added new perspectives to our understanding of the genetic component of cardiac diseases associated with sudden cardiac death. 1 Genetic testing has progressed in the clinical setting, and is now broadly used in diagnostics, risk stratification, and therapeutic strategies. With the increased availability of fast and cost-effective technologies, genetic testing is in the process of shifting from a targeted approach, whereby specific genes are analyzed based on particular symptoms or family histories, to sequencing an entire exome or genome. However, by shifting the paradigm to analyzing whole exomes or genomes, it has become increasingly clear that rare variation in the human genome is more abundant than previously thought. Reasonably, many of these rare variants have little to no monogenetic effect on health conditions. In fact, target-sequencing approaches could have led to faulty conclusions, due to biased pre-assumptions, which are then again reinforced by the finding. 2 Many publicly available genomic databases are now available.
These contain data on thousands of individuals from the general population, which assists researchers and clinicians in evaluating whether a genetic variant is the causal variant or plain background noise. Also, recent joint recommendations from the American College of Medical Genetics (ACMG) and Association for Molecular Pathology (AMP), have provided new guidelines in how to critically review a genetic result. 3 This review will be focusing on genetics within the field of cardiology. The aim is to discuss the controversies of early genetic testing-from incidental findings to the consequences of these in a clinical setting. The clinical utility of publicly available databases will also be discussed, and how these can be employed to highlight dubitable variants that have been implicated with cardiac channelopathies in the early day of genomics-based medicine. Finally, some of the current limitations in modern genetics, and how these may be resolved in the nearby future will also be reviewed. Although, parts of this cautionary review are known to clinical geneticists and genetic counselors, many clinicians within the field of cardiology, might not be aware of the potentials and perils of every-day genetics.
| HOW EARLY DAY GENETIC TESTING BECAME AN ISSUE
Before the onset of large-scale genetic studies, the scientific community was misled by the belief that genes previously linked with highly monogenic causes of, e.g., long QT syndrome (LQTS), could not contain rare innocuous genetic variants; thus any genetic finding in these "irrefutable" genes were in many cases given a disease-causing status. 4 Nearly 10 to 15 years ago, the initial screening panel for LQTS only contained the 3 major susceptibility genes KCNQ1, KCNH2 and SCN5A. 5, 6 There are numerous examples in the literature, where if a rare genetic variant was identified in these canonical genes, and the same variant was absent in only 50 to 200 healthy control subjects (100-400 alleles), this was often enough evidence for the variant to be labeled as pathogenic. [7] [8] [9] [10] The number of healthy controls was later increased, with mandatory control numbers of at least 1000 alleles, to insure that the identified variant had an allele frequency below the polymorphism threshold at that time (minor allele frequency [MAF] of 0.5%-1%). 4 Although a previous study has shown that rare non-synonymous variants do lead to amino acid changes, and are more probably to be deleterious at a protein level, rarity does not automatically imply disease causality. 11 In 2015, our group conducted a study, where over 6000 ostensibly healthy individuals randomly selected from the general population were screened for variants previously associated with LQTS. 12 Based on the generally accepted phenotype prevalence of LQTS of 1 in 2000 individuals in the general population, one would expect that around 3 individuals in the dataset would have manifest LQTS. 13 In total, we identified 243 individuals carrying a mutation previously associated with the monogenic cause of LQTS. All of the carriers exhibited QTc-intervals within the normal range, did not have an increased propensity for syncope, and had identical mortality rates compared with non-carriers. 12 These results illustrate that rarity does not automatically lead to pathogenicity and that any novel genetic finding needs to be carefully scrutinized, before being given a disease-causing label. Several research groups have estimated that at least 10% of the variants associated with LQTS may have been classified inaccurately. 14, 15 In addition, the pathogenicity of a large fraction of variants and even whole genes previously associated with dilated cardiomyopathy (DCM), Brugada syndrome (BrS), sudden infant death syndrome and catecholaminergic polymorphic ventricular tachycardia has been challenged. [16] [17] [18] [19] [20] Thus, the issue of incidental genetic findings might be a larger problem than initially anticipated. probably at a frequency equivalent to or lower than that seen in the general population. This is important to bear in mind, as these types of databases are made possible through collaborative efforts from different population-based cohorts enriched with phenotypes, for which the studies were originally initiated. The general eligibility of the dataset to be used as a reference has been published in a recent report by Lek and the Exome Aggregation Consortium. 25 The online databases are summarized in Table 1 .
| HIGHLIGHTING POTENTIAL BENIGN BYSTANDERS USING EXOME DATABASES
The ExAC and the gnomAD can be used to "rule out" benign variants and reduce the risk of false-positive variants. As the gnomAD is still in beta-mode, the ExAC will be used to show an example. The LQTS is an autosomal dominant inherited channelopathy, and the vast majority of LQTS cases is caused by mutations in KCNQ1, KCNH2 and SCN5A. As mentioned previously, the LQTS phenotype prevalence is estimated to be 1 in every 2000 individuals. 26 In a large database, such as the ExAC containing more than 60 000 individuals, one would expect to identify Using publicly available exome databases, putative benign variants previously associated with highly penetrant autosomal disease can be highlighted. Subsequently, highlighted variants must be evaluated in concert with clinical data, family information and functional analyses, and caution must be exercised when assessing traits with polygenic inheritance, multifactorial inheritance, or traits associated with reduced penetrance, age-related penetrance and/or variable expressivity. 29 Variants associated with LQTS and identified in ExAC have been curated, using the ACMG criteria for pathogenicity, and summarized in the Tables S1 and S2, Supporting Information. In Table 2 The lack of ethnic diversity is not only restricted to candidategene studies. A study from 2009 revealed that 96% of participants in genome-wide association studies (GWAS) were based on individuals of European descent. 44 Such studies scan the genomes of thousands of people to find common variants associated with disease traits. 45 This finding prompted warnings that a much larger variety of populations should be studied to avoid genomic medicine only benefitting individuals of European descent. Over the last decade, the number of individuals included in GWAS who are of non-European descent has risen to approximately 20%. 46 The majority of this increase is due to studies being conducted on Asian populations, 47 whilst the degree of studies on populations of African and Latin American ancestry has hardly changed. 48 Until GWAS and next-generation sequencing studies have been conducted on major ancestral population across the globe, we will continue to lack imperative information on disease biology. The numerous associations between variants and diseases, and between variants and drug response observed in populations of European descent, will be difficult to extrapolate to other non-European populations without proper interrogation. For instance, for up to 25% of the variants identified in European Americans through GWAS and associated with type 2 diabetes or body mass index, the associations differ in at least 1 of 5 populations of non-European descent. 49 This could potentially indicate that variants can have different risk profiles depending on the ancestry involved.
| CLINICAL CONSEQUENCES OF DOUBT
Even though we today know that the mere presence of a rare variant in indisputable genes does not automate a deleterious translation, the prior bystanders are still causing physicists problems in the clinical setting when assessing genetic testing results. In a recent study by
Van Driest et al, the authors showed considerable discordance between different genetic test companies and ClinVar. 50, 51 Three expert laboratories were queried to evaluate the pathogenicity of rare genetic variants in KCNH2 and SCN5A previously associated with the BrS or LQTS using internal classification guidelines. The study showed that consensus was only reached for 2 of the 42 rare variants (4.8%), potentially due to different reference databases, annotation tools, and different thresholds for defining pathogenicity. shocks and surgery-related complications. 53 Secondly, a misdiagnosis can also give rise to over cautious actions, for example, advising patients to abstain from childhood contact sports and activities. Additional concerns are related to the psychological consequences, such as turning the patient into the "worried well," with frequent need of reassurance by a health care professional. 54 Thirdly, a genetic diagnosis can have sizable impact on financial issues, such as medical bills and health insurance. 55 Lastly, when the status of a variant is changed from pathogenic to benign, the sequencing laboratory often recontacts the referring physician, who in turn informs the patient and their tested family members, engendering confusion and distrust. 56 
| FUTURE PERSPECTIVES
In order to reach concordance between expert laboratories, efforts on securing that all clinical laboratories have access to the most extensive variant and phenotype information available are warranted.
Also, improved guidelines in interpreting and classifying a genetic result are vital. Concerns regarding the latest recommendations by ACMG have been raised in a recent report by Amendola et al. 57 Nine laboratories were invited to classify 9 variants, and an additional 90 variants were randomly distributed to 3 of 9 laboratories. When the laboratories applied their own internal classification criteria, the inter-laboratory concordance was 34%, which was not superior to previous laboratory developed classification guidelines. However, when the laboratories were asked to classify the variants applying the most recent ACMG criteria, their concordance level did not increase. Through in-depth discussion among the laboratories, by implementation of disease-and gene-specific criteria, as well as clarification of the guidelines, the inter-laboratory concordance rate increased from 34% to 71%. Although consensus was raised through discussion, it is important to note that increased level of agreement does not automate disease-causality. The aim is not simply to agree with one another in our classification and methods, but also to ensure that our classifications are correct and will hold over time. One of the main reasons to inconsistency between laboratories when interpreting variants has been reliance on unpublished internal data. Different information on variants between laboratories will unavoidably lead to different interpretation. Hence, in order to obtain consistent variant interpretation regardless of laboratory, there is a demand for public availability to relevant variant-specific data. Individual (and not necessarily clinical) laboratories should be encouraged to share (unpublished) data by depositing it to public repositories, such as ClinVar. 51 In fact, a recent study showed that laboratories increased interpretation concordance from 88.3% to 91.7% after sharing internal data. 63 Also uniform access to the most recent information on sequenced data is needed, in order to avoid differences in classification and need for reassessment over short periods of time. This is particularly important for genes whose role in disease is newly established where data on functional and clinical consequence accumulate rapidly. 64 Part of the difficulty of variant annotation is due to the general lack of genetic information on other non-white ethnic populations.
Regions such as the Middle East, South Asia as well as Western Africa are poorly genetically characterized, and remain an important issue in contemporary genetic medicine. Efforts on collecting large sequence data and phenotypic data of individuals (preferably more than 10 000 individuals) from different ancestral backgrounds and regions will undoubtedly improve variant classification and aid in correct genetic counseling regardless of ancestral background.
| CONCLUSION
Clinical genetic testing is rapidly evolving, and generates an unprecedented amount of sequence variation to be interpreted and in a larger variety of genes than we have sequenced in the past. Despite the increase of data available, variant interpretation remains an important task in modern genetics, and better methods are warranted. Large publicly available reference databases have provided important insight into the location and nature of genetic variation, which in turn has improved variant interpretation and classification. In order to avoid interpretation discordance between clinical laboratories, future guidelines should include gene-specific descriptions and detailed instructions in how to apply guidelines. Also, continuous efforts in sharing of data between laboratories, researchers, and clinicians will indubitably prove paramount in future variant classification. In combination with our rapidly growing understanding of the human genome, these efforts will indubitably improve our ability to make rational use of genomics in medical care.
